Table 2.
Treatment details of 143 eligibile patients with ATRT
| Total | % | |
|---|---|---|
| Extent of surgical resection | ||
| Complete | 49 | 34 |
| Incomplete | 94 | 66 |
| HDCT | ||
| Yes | 34 | 24 |
| No | 109 | 76 |
| Completed chemotherapy according to EU-RHAB | ||
| Yes | 107 | 75 |
| No | 36 | 25 |
| Radiotherapy# | ||
| Yes | 81 | 87 |
| No | 12 | 13 |
| Complete remission | ||
| Yes | 76 | 53 |
| After surgery | 23 | |
| After chemotherapy | 53 | |
| No | 67 | 47 |
| Progression | ||
| No | 52 | 36.5 |
| PD on CT* | 49 | 34 |
| PD after CT** | 42 | 29.5 |
| SAE | n = 20 | |
| VOD§ | 11 | |
| CNS toxicities& | 5 | |
| Severe infection (pneumonia) | 1 | |
| AML*** | 3 | |
| Present status | ||
| CR | 44 | 31 |
| Stable disease | 10 | 7 |
| Progressive disease | 7 | 5 |
| Death | 82 | 57 |
Abbreviations: CR, complete remission; CT, chemotherapy; HDCT, high dose chemotherapy; PD, progressive disease; SAE, serious adverse event; VOD, veno-occlusive disease; AML, acute myeloid leukemia.
#Only patients >12 months at diagnosis (n = 93) were analyzed.
*During CT, analyzed within 4 months from diagnosis.
**After CT, <1 year from diagnosis.
§All VOD resolved.
&2 infections, 2 leukoencephalopathies, 1 central apnea.
***32, 23, and 53 months from diagnosis. Two of them died due to AML (one with SD of the ATRT and no GLM, the other with a GLM in SMARCB1 in CR of the ATRT). The third patient continues to be in CR following GTR for ATRT and is in first CR following chemotherapy for AML which was diagnosed 4 years after the diagnosis of ATRT.
110 patients were from German speaking countries (Germany, Austria, and Switzerland), the remainder (n = 33) from the Czech Republic, Denmark, Norway, Sweden, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, and Spain.